Delineating pro-angiogenic myeloid cells in cancer therapy

Benjamin W. Johnson, Bhagelu R. Achyut, Sadanand Fulzele, Ashis K. Mondal, Ravindra Kolhe, Ali S. Arbab

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of the myeloid cell displaying angiogenic properties in solid tumors. There is an urgent need to delineate angiogenic myeloid cell populations in order to facilitate specific targeting of protumor myeloid cells among heterogeneous pool. This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy.

Original languageEnglish (US)
Article number2565
JournalInternational journal of molecular sciences
Issue number9
StatePublished - Aug 2018


  • Angiogenic
  • Antiangiogenic
  • Chemotherapy
  • Immunotherapy
  • MDSC
  • Myeloid
  • Radiotherapy
  • Tumor

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Delineating pro-angiogenic myeloid cells in cancer therapy'. Together they form a unique fingerprint.

Cite this